The Ministry of Public Health department for pharmacy, medicines and laboratories, whose director reported in March 2025 on preparing a separate Cameroonian Medicines Agency. Cameroon is not on WHO's list of regulators at maturity level 3 or 4.
Medicines regulation in Cameroon is carried out within the Ministry of Public Health, and a separate medicines agency is still being prepared. The Ministry's March 2025 report on pharmaceutical regulation brought together this Department, the Inspectorate General of Pharmaceutical Services and Laboratories, the national quality control laboratory (LANACOME) and the national essential medicines supply centre (CENAME), and referred to the missions of a national pharmaceutical regulatory authority (Autorité Nationale de Réglementation Pharmaceutique) in a report by the Department of Operational Health Research. The coordinates are an approximate Yaoundé city point.
At a meeting on 12 March 2025 the Department's director reported that, after Cameroon ratified the African Union treaty on the African Medicines Agency, a road map and a draft text creating a Cameroonian Medicines Agency (Agence Camerounaise du Médicament) had been prepared, with a sustainability study to follow. The same meeting reported ten applications for clinical trial authorisation in 2024, two of them in progress, on subjects including malaria, cancers, tuberculosis and hepatitis, and 577 pharmaceutical batches received by LANACOME. WHO's list of regulators operating at maturity level 3 or 4, updated August 2026, does not include Cameroon. A 2026 study interviewing 57 people across the chemotherapy supply chain, one of them a regulator, named weak regulatory systems, underfunded regulatory work and high prices as reasons substandard cancer medicines circulate.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/